Related by context. All words. (Click for frequent words.) 67 pharmacological interventions 66 pharmacologic intervention 65 nonpharmacologic 65 antioxidant supplementation 64 CAM modalities 64 pharmacological therapies 64 antiplatelet therapies 63 psychopharmacological 63 dietary modification 63 STEP BD 63 antiangiogenic therapy 63 nonpharmacological 63 poststroke depression 63 pharmacologic treatments 63 pharmacologic interventions 63 β blockers 62 stratifying patients 62 antidepressive 62 empiric 62 pharmacological treatments 62 pharmacological intervention 62 RISPERDAL ® 62 DHEA supplementation 62 testosterone supplementation 62 intensive lipid lowering 62 SSRI antidepressant 62 topical NSAIDs 61 cognitive behavioral therapies 61 pharmacogenetic testing 61 statins cholesterol lowering 61 oral antidiabetes drugs 61 Genetic predisposition 61 antiangiogenic agents 61 statin medications 61 psychosocial variables 61 oral anticoagulation 61 colorectal carcinogenesis 61 antiplatelet medications 61 riociguat 61 guideline concordant 61 biologic plausibility 61 Cognitive therapy 61 biopsychosocial 61 lipid lowering medication 61 pharmacological approaches 61 psychopharmacologic 61 insulin analogs 61 underlying pathophysiology 61 pharmacotherapeutic 61 biopsychosocial model 61 immunosuppressive regimens 61 mTOR inhibition 61 pharmacological therapy 61 cognitive enhancer 60 physiologic mechanisms 60 renoprotective 60 opiate dependence 60 inhaled bronchodilators 60 endophenotypes 60 residual confounding 60 lipid lowering medications 60 TNF alpha inhibitor 60 probiotic supplementation 60 ketogenic diets 60 neuropsychiatric diseases 60 comorbid disorders 60 differential gene expression 60 neuroleptic 60 neuroactive 60 prognostic indicators 60 neuroleptic drugs 60 Helicobacter pylori eradication 60 antithrombotic therapy 60 thromboembolic disease 60 IntroductionThe 60 unmeasured factors 60 therapeutic regimens 60 chemosensitivity 60 pharmacokinetic interactions 60 pathophysiological processes 60 antihypertensive drugs 60 somatoform disorders 59 empiric therapy 59 thiopurine 59 serum biomarkers 59 nutrient supplementation 59 pharmacologic approaches 59 dyslipidemias 59 underlying molecular mechanisms 59 nosology 59 aldosterone antagonist 59 clomipramine 59 elevated CRP 59 insulin analogues 59 neuropsychological impairments 59 comorbid depression 59 agomelatine 59 APOE genotype 59 pyridostigmine 59 type2 diabetes 59 antidepression 59 unmeasured confounding 59 nonadherence 59 Hedgehog inhibitor 59 antihypertensive therapy 59 anti dyslipidemic 59 pharmacotherapies 59 psychotherapeutic interventions 59 subclinical atherosclerosis 59 pharmacogenetic 59 developmental neurotoxicity 59 antiresorptive 59 therapeutic equivalence 59 serum lipid 59 predictive biomarkers 59 diagnosing ADHD 59 biochemical abnormalities 59 CINQUIL 59 lipid lowering agents 59 antiplatelet drugs 59 methodological limitations 59 Cognitive behavioral 59 eprotirome 59 EGFR mutation status 59 meta analytic 59 leukotriene receptor antagonists 59 molecular determinants 59 neuroleptics 58 dietary interventions 58 prostate carcinogenesis 58 BRAF inhibitors 58 pleiotropic effects 58 antidepressant efficacy 58 diathesis 58 dyslipidaemia 58 stimulate neurogenesis 58 generalisability 58 functional gastrointestinal disorders 58 tranylcypromine 58 antiplatelets 58 dual antiplatelet 58 AChE inhibitors 58 hematopoietic cancers 58 H. pylori eradication 58 late onset hypogonadism 58 lipid lowering therapies 58 antiarrhythmic 58 tricyclic antidepressant 58 nomograms 58 convergent validity 58 pharmacoeconomic 58 topical retinoids 58 unmeasured confounders 58 Subgroup analyzes 58 Corus CAD 58 erythropoietic 58 treating neuropathic pain 58 serotonin deficiency 58 pathophysiological mechanisms 58 flecainide 58 biologic DMARDs 58 cardiotoxic effects 58 Calcium intake 58 psychotherapies 58 atypical antipsychotic medications 58 antithrombotic agents 58 albumin excretion 58 warfarin dosing 58 cardioprotective effects 58 conditional logistic regression 58 neuropsychiatric symptoms 58 efficacy tolerability 58 neuroregenerative 58 aspirin clopidogrel 58 therapeutic armamentarium 58 Calorie restriction 58 LDL lowering 58 emotional dysregulation 58 G. biloba 58 lung cancer chemoprevention 58 immunomodulation 58 CB1 antagonists 58 Valdoxan 58 cranial irradiation 58 Lofexidine 58 pharmacogenomic testing 58 metaanalysis 58 neurobiological underpinnings 58 paroxetine sertraline 58 hematological parameters 58 antitumor efficacy 58 DNA methylation markers 58 mechanistic insights 58 selenium supplementation 58 amyloid hypothesis 58 pathophysiologic mechanisms 58 prostaglandin analogues 58 reboxetine 58 psychiatric comorbidity 58 dysfunctional voiding 58 NUCYNTA R 58 thromboprophylaxis 58 comorbid illnesses 58 Cytolin R 58 erythropoietic agents 58 metabonomics 58 stimulant ADHD 58 randomized controlled trials RCTs 58 prognostic biomarkers 57 aetiology 57 neuropsychological assessment 57 chemopreventive agent 57 cardiac repolarization 57 anti angiogenic drugs 57 antithrombotics 57 mitochondrial toxicity 57 inherited predisposition 57 monoamine oxidase inhibitors 57 causal pathway 57 trastuzumab Herceptin ® 57 familial predisposition 57 inhaled corticosteroid therapy 57 QTc intervals 57 ADME properties 57 empirically validated 57 carotid IMT 57 anticholinergic agents 57 overactive bladder symptoms 57 paricalcitol 57 fusion enhancers 57 topical calcineurin inhibitors 57 preclinically 57 HCV protease inhibitors 57 nutritional supplementation 57 amisulpride 57 COX 2s 57 COPD exacerbations 57 tumor subtype 57 triglyceride lowering 57 Insulin detemir 57 ALK inhibitors 57 anti TNFs 57 meta cognitive 57 chemopreventive agents 57 apneic episodes 57 GnRH agonists 57 tiagabine 57 adjuvant therapies 57 stavudine d4T 57 pathogenetic mechanisms 57 BRCA testing 57 murine models 57 KIF6 carriers 57 fluoxetine Prozac 57 lipid lowering therapy 57 plasma pharmacokinetics 57 dietary antioxidants 57 oral antidiabetes 57 Cognitive impairment 57 viral kinetics 57 antipsychotics antidepressants 57 hypomanic episodes 57 etiological 57 prognostically 57 aetiological 57 aromatase inhibitors AIs 57 p# activation 57 pressor response 57 rEV# 57 newer atypical antipsychotics 57 sociodemographic factors 57 impair fertility 57 etiologic 57 adrenal suppression 57 pathophysiologic 57 lowering blood glucose 57 bronchopulmonary dysplasia BPD 57 hawthorn extract 57 Combination therapy 57 potassium sparing diuretics 57 meta regression 57 Alequel 57 premorbid 57 perinatal outcomes 57 psychosocial stressors 57 Bergenstal 57 prostanoid 57 methodologically rigorous 57 pharmacodynamic properties 57 pharmacodynamic parameters 57 pharmacologic therapy 57 neurocognitive impairment 57 psychobiological 57 EFFEXOR XR 57 neurobiological mechanisms 57 ß blockers 57 atypical neuroleptics 57 hypoxic tumors 57 EBV infection 57 inhaled glucocorticoids 57 PITX2 methylation 57 neuropsychological impairment 57 intracranial stenosis 57 cardioprotection 57 fulvestrant 57 antianginal 57 antitumor effect 57 imatinib resistance 57 ACCORD Lipid 57 gastrointestinal absorption 57 opiate analgesics 57 neurocognitive deficits 57 immunosuppressive regimen 57 venous thromboembolism VTE prophylaxis 57 mutated K ras 57 nutrigenomic 57 antiangiogenesis 57 PDE# inhibitors 57 Multiple logistic regression 57 folate supplementation 57 CYP#D# inhibitor 57 lipid lowering drugs 57 MAGE A3 ASCI 57 CaPre ™ 57 antiarrhythmic drug 57 antidiabetic drugs 57 periprocedural MI 57 Pfizer Aricept 57 interpersonal psychotherapy 57 antimicrobial prophylaxis 57 IgG1 antibodies 57 resynchronization therapy 56 KRAS status 56 induce remission 56 calcium antagonists 56 neurobiological basis 56 EEG abnormalities 56 Dr. Chodick 56 pharmacogenetic tests 56 haemodynamic 56 fibrate drugs 56 adjuvant systemic 56 synthetic lethality 56 sonographic diagnosis 56 potentially modifiable 56 etiologic factors 56 coagulation abnormalities 56 SILENOR 56 androgen depletion 56 insulin sensitization 56 contraindicate 56 isoflavone supplement 56 hoFH patients 56 Aggrastat ® tirofiban hydrochloride 56 stone formers 56 DVT prophylaxis 56 antihypertensive agents 56 subclinical cardiovascular disease 56 BEXXAR therapeutic regimen 56 oncological outcomes 56 SPRIX ® 56 platelet activation 56 ConclusionThis 56 hypochondriasis 56 inflammatory biomarkers 56 postmenopausal estrogen 56 detecting diagnosing 56 NMDA antagonists 56 lowering homocysteine 56 imexon 56 immunosuppressive therapies 56 atherosclerotic vascular disease 56 Eli Lilly Cymbalta 56 COMT inhibitors 56 recurrent miscarriage 56 AZILECT ® 56 oral antidiabetic 56 nonnucleoside reverse transcriptase inhibitors 56 Rheos System 56 RAS blockers 56 antidiabetic medications 56 maximally tolerated 56 ganaxolone 56 multivitamin supplementation 56 Singh Manoux 56 dosing frequency 56 intranasal corticosteroids 56 akinetic mutism 56 either acutely decompensated 56 Mechanistic studies 56 venlafaxine Effexor 56 thrombophilia 56 PROCHYMAL 56 prognostic markers 56 maximally tolerated lipid lowering 56 Bisphosphonate 56 abrupt discontinuation 56 biological plausibility 56 pharmacodynamic markers 56 dosage regimen 56 hormone therapy HT 56 Cytolin ® 56 pathogenic mechanisms 56 PPARγ 56 urinary biomarkers 56 neurodevelopmental outcomes 56 BEXXAR Therapeutic Regimen 56 glucose homeostasis 56 multifactorial disease 56 iron chelators 56 comorbid conditions 56 neurosensory 56 atherothrombotic 56 anxiolytics 56 radiographic outcomes 56 molecularly targeted therapies 56 migraine prophylaxis 56 anticlotting drugs 56 Selective Serotonin Reuptake Inhibitor 56 Suicidal ideation 56 ACCOMPLISH 56 melatonin supplements 56 pegylated IFN 56 subthreshold depression 56 epigenetic mechanisms 56 genotype phenotype 56 therapeutic modalities 56 molecular abnormalities 56 HeFH 56 antidiabetic 56 secondary amenorrhea 56 Non inferiority 56 IOP lowering 56 macrolide antibiotics 56 OnDose TM 56 serotonin reuptake inhibitors 56 aldosterone antagonists 56 immune reconstitution 56 pentoxifylline 56 pharmacokinetic equivalence 56 hepatotoxic 56 antiepileptics 56 SSRI SNRI 56 acamprosate 56 ATACAND 56 memantine Namenda 56 IV bisphosphonates 56 pathophysiological 56 varenicline Chantix 56 antiangiogenic agent 56 pharmacologic 56 angiotensin receptor blockers ARBs 56 postoperative AF 56 lenalidomide dexamethasone 56 thyrotropin levels 56 estimated GFR 56 ALI ARDS 56 CAPHOSOL 56 hyperuricaemia 56 HIF PH inhibitors 56 oxcarbazepine 56 sotalol 56 neurocognitive function 56 insulin sensitizing drug 56 INVEGA ® 56 Cochrane reviewers 56 multi factorial disease 56 EECP ® therapy 56 myopathy rhabdomyolysis 56 psychiatric comorbidities 56 pharmacokinetic characteristics 56 adipiplon 56 chronicity 56 tecarfarin 56 hypericin 56 thiazide 56 ticagrelor Brilinta 56 intestinal motility 56 serum PTH 56 LHRH antagonists 56 CYP #A# 56 ULTRAM ER 56 Randomised controlled trials 56 RNAi therapeutic targeting PCSK9 56 oncologic outcomes 56 S. maltophilia 56 PPAR gamma agonists 56 MBCT 56 NATRECOR ® 56 folic acid vitamin B# 56 Cognitive behavioral therapy 56 TNF alpha antagonist 56 randomizing patients 56 optimal dosing 56 blood thinner Warfarin 56 ZOLINZA 56 microdose 56 lipid abnormalities 56 C1 INH deficiency 56 thyrotropin 56 anti angiogenic agents 56 confounder 56 Zevalin consolidation 56 boosted protease inhibitor 56 causal inference 56 inhibit platelet function 56 Mindfulness Based Cognitive Therapy 56 COPD sufferers 56 bone metabolism 56 bendroflumethiazide 56 Fasting glucose 56 MEVACOR 56 homocysteine concentrations 55 Observational studies 55 dietary carbohydrate 55 Multiple linear regression 55 SERMs 55 loop diuretics 55 androgen deficiency 55 BENICAR HCT 55 Aviptadil 55 behavioral interventions 55 Alpha lipoic acid 55 refractive correction 55 antitumour 55 anti tubercular 55 HER2 overexpression 55 cognitive enhancers 55 VCUG 55 ovulatory cycles 55 SIADH 55 linear pharmacokinetics 55 inotropic agents 55 Adjuvant therapy 55 antiandrogens 55 insulin sensitizing 55 validating biomarkers 55 efficacious therapies 55 analgesic medications 55 PYY nasal spray 55 oxysterols 55 constipation OIC 55 thetreatment 55 cetirizine Zyrtec 55 thyroid deficiency 55 topiramate Topamax 55 nonpharmacologic interventions 55 Lu AA# 55 CETP inhibition 55 intravenous cyclophosphamide 55 K ras mutations 55 HPA axis 55 norepinephrine reuptake inhibition 55 intact parathyroid hormone 55 convenient dosing regimens 55 tumor histology 55 compensatory mechanisms 55 vidofludimus 55 Perforomist ™ Inhalation Solution 55 flavopiridol 55 antiemetics 55 EGFR tyrosine kinase inhibitors 55 somatostatin analogs 55 predictive validity 55 adverse cytogenetics 55 postoperative delirium 55 FTIs 55 PDE7B 55 insulin sensitizing agents 55 postprandial hyperglycemia 55 tumor hypoxia 55 HIV tropism 55 spontaneous regression 55 antihormonal 55 postoperative radiotherapy 55 Oral corticosteroids 55 Genetic variants 55 uridine triacetate 55 Dr. Cliby 55 doxorubicin HCl 55 Randomized clinical trials 55 intravenous immunoglobulin IVIg 55 antidepressant paroxetine 55 sertraline Zoloft 55 Inhaled corticosteroids 55 CKD MBD 55 ADAGIO study 55 Cardiorespiratory fitness 55 familial clustering 55 CIMZIA ™ 55 mGluR2 NAM 55 fermentable carbohydrates 55 haematologic 55 Venlafaxine 55 aerosolized surfactant 55 diagnostic biomarker 55 potassium sparing 55 DNA methylation patterns 55 inotropes 55 antibiotic prophylaxis 55 preterm neonates 55 opioid antagonists 55 vildagliptin 55 CYP#D# genotype 55 Src inhibitors 55 Cognitive Behavioural Therapy CBT 55 Provent Therapy 55 Quantitative EEG 55 neurophysiologic 55 inhibiting mTOR 55 immunostimulatory effects 55 disulfiram 55 Pathological gambling 55 medication nonadherence 55 HIV HCV coinfected 55 thalidomide Thalomid 55 tipranavir 55 oral antiplatelet 55 angiogenesis inhibition 55 pravastatin Pravachol 55 Generalised Anxiety Disorder 55 IDH mutations 55 CTAP# Capsules 55 genomic biomarker 55 glitazones 55 maturational 55 MMP inhibitors 55 sirtuin activators 55 intensive statin therapy 55 platelet inhibition 55 physico chemical properties 55 inactivated influenza vaccines 55 Liver transplantation 55 chlamydial infection 55 Anti psychotics 55 sulphonylureas 55 LV dysfunction 55 lipoprotein levels 55 COX enzymes 55 pituitary hormone 55 diagnostic modality 55 metabolic dysfunction 55 platelet reactivity 55 cardiotoxic 55 lung epithelium 55 analgesic effects 55 adjunctively 55 VTE prophylaxis 55 SLC#A# [002] 55 Carotid endarterectomy 55 HAART regimens 55 tumor subtypes 55 treating menopausal symptoms 55 beta carotene supplementation 55 TMP SMX 55 anti angiogenic therapy 55 Dapagliflozin 55 DFMO 55 alkalosis 55 adjuvant endocrine 55 fructose intake 55 ergot alkaloids 55 symptomatic hyponatremia 55 myocardial dysfunction 55 genotypic resistance 55 lipid parameters 55 tamoxifen Nolvadex ® 55 Effexor venlafaxine 55 hemodilution 55 lipoprotein metabolism 55 metabolic dysregulation 55 developmental trajectories 55 hereditary predisposition 55 bioactive components 55 procalcitonin 55 urolithiasis 55 airway responsiveness 55 Relapsing remitting MS 55 chlorpromazine 55 FENO 55 CVD cardiovascular disease 55 endothelin antagonists 55 pharmacological 55 fluoroquinolone resistance 55 pre malignant lesions 55 ibudilast 55 oral prednisolone 55 endocrinologic 55 pharmacodynamic effects 55 heparanase 55 Teriparatide 55 Pagoclone 55 medicalisation 55 neuroprotectant 55 mechanistic studies 55 microRNA biomarkers 55 pretest probability 55 sargramostim 55 HbA1C 55 mania hypomania 55 glycosylated hemoglobin HbA1c 55 thiazides 55 adrenal function 55 relapsed ALL 55 N acetylcysteine 55 scintigraphic 55 non selective NSAIDs 55 intima media thickness 55 SUTENT ® 55 phenotypic expression 55 glycated hemoglobin levels 55 Topical corticosteroids 55 genetic susceptibilities 55 diabetic kidney 55 florbetaben 55 genetic polymorphisms 55 GABRA2 gene 55 estrogen metabolism 55 relieving menopausal symptoms 55 postmenopausal hormone replacement 55 subclinical disease 55 immunotherapeutic approaches 55 Combination antiretroviral therapy 55 antiplatelet agents 55 curative therapy 55 putative biomarkers 55 atherogenic dyslipidemia 55 nonalcoholic steatohepatitis NASH 55 long acting bronchodilator 55 sJIA 55 behavioral disinhibition 55 poor metabolizers 54 glial tumors 54 beta blocker therapy 54 Vitamin D supplementation 54 statin simvastatin 54 cardio metabolic 54 small molecule activators 54 nonpharmacological treatments 54 prodromal phase 54 pregabalin Lyrica 54 tumor necrosis 54 progressive dyspnea 54 neural substrates 54 pharmaco 54 allogeneic HSCT 54 factor Xa inhibitor 54 cediranib 54 biphosphonates 54 immunomodulatory effects 54 hepatic toxicity 54 LAB CGRP 54 D Tagatose 54 Technosphere Insulin 54 Abbott Trilipix 54 medicalizing 54 synthetic retinoid 54 perioperative morbidity 54 MAO inhibitors 54 psychoeducation 54 depot antipsychotics 54 neuroprotective agent 54 antimetabolites 54 antidepressants fluoxetine 54 renal denervation 54 HF ACTION 54 multidrug 54 difficulty swallowing tablets 54 HMG CoA reductase inhibitors 54 Zoloft sertraline 54 methylation markers 54 postmarketing surveillance 54 underdiagnosis 54 premenstrual syndrome PMS 54 Nalmefene 54 Randomized trials 54 atypical femur fractures 54 NPM1 mutation 54 Meta analyzes 54 Levothyroxine 54 secondary hyperparathyroidism 54 antimuscarinic 54 virological suppression 54 microvascular dysfunction 54 atherosclerotic renal artery stenosis 54 Membrane proteins 54 antihyperglycemic 54 prostate cancer CaP 54 Electroconvulsive therapy 54 anticoagulant warfarin 54 orthomolecular medicine 54 delayed gastric emptying 54 prospectively stratified 54 NUCYNTA ™ 54 endocrinological 54 multifocal IOLs 54 IVIG therapy 54 nociceptive pain 54 coadministration 54 KDOQI 54 anticholinergic effects 54 NNT = 54 GLP 1R 54 anticonvulsant medications 54 inflammatory bowel syndrome 54 neovascular diseases 54 CA9 SCAN 54 d dimer 54 paroxetine Paxil 54 Angiotensin receptor blockers 54 antihypertensive medications 54 ablative therapy 54 β blocker 54 vitamin D sufficiency 54 idraparinux 54 nongenetic 54 chlorthalidone 54 Symadex 54 Interferon beta 54 cardiovascular calcification 54 sedating medications 54 etiological factors 54 erlotinib Tarceva 54 Prof. Krainer 54 Treg cell 54 labetalol 54 Valproate 54 urate lowering 54 PDE7 inhibitors 54 INVEGA ™ 54 G6PD deficiency 54 Cardiotoxicity 54 Elevated triglycerides 54 medicine EBM 54 clevidipine 54 pharmacokinetic interaction 54 immuno suppressive 54 CYP#A# inhibitors 54 endoxifen 54 SIRT1 activation 54 allergen avoidance 54 Logistic regression 54 Personalised medicine 54 genetic locus 54 systemic hypotension 54 MS relapses 54 methodologic 54 Antidepressant medications 54 antiinflammatory drugs 54 PNH patients 54 NexACT ® 54 therapy CBT 54 obstetric complications 54 Limbrel 54 endogenous opioid 54 bronchial inflammation 54 corneal neovascularization 54 Tasigna prolongs 54 Comparative effectiveness 54 HER2 expression 54 pharmacologic therapies 54 telomerase activation 54 noncognitive 54 psychoactive medications 54 Inhaled nitric oxide 54 antirheumatic 54 KRAS mutation 54 Secondary efficacy endpoints 54 dosage regimens 54 NCCN guidelines 54 symptomology 54 Buhimschi 54 systemic corticosteroid 54 polyp recurrence 54 Symbicort SMART 54 incidentalomas 54 oral NSAIDs 54 prophylactic therapy 54 thienopyridines 54 oral talactoferrin 54 ALTTO 54 William Sandborn MD 54 sociodemographic characteristics 54 Selective serotonin reuptake inhibitors 54 AGHD 54 mixed hyperlipidemia 54 bile acid metabolism 54 gene loci 54 hypercalciuria 54 Multivariate logistic regression 54 generalizability 54 echocardiographic parameters 54 neuroinflammatory 54 multivariate analyzes 54 diabetic polyneuropathy 54 postmenopausal hormone therapy 54 CARE HF 54 immunopathology 54 perfusion CT 54 antiarrhythmic drugs 54 psychotherapeutic treatments 54 pimozide 54 Imipramine 54 canakinumab 54 mGluR5 inhibition 54 chronic myocardial ischemia 54 opioid dependent 54 pure fructose 54 serum cotinine 54 electrophysiologic 54 chemopreventive 54 pleiotropy 54 perfusion MRI 54 rEEG 54 vascular endothelial dysfunction 54 plasma homocysteine 54 SRBD 54 metformin Glucophage 54 amino acid leucine 54 steroid inhalers 54 tamoxifen metabolism 54 relapsed ovarian cancer 54 mechanistic explanation 54 Cancidas 54 CVD mortality 54 NanoCrystal Technology 54 molecular underpinnings 54 donepezil Aricept 54 hypercholesterolemia 54 galantamine 54 vitamin supplementation 54 protease inhibitor PI 54 activate AMPK 54 VADT 54 metabolomic profiling 54 hsCRP levels 54 ART regimens 54 GABRA2 54 baclofen 54 dosing algorithm 54 sideeffects 54 routine episiotomy 54 AST ALT 54 sibutramine Meridia 54 comorbid anxiety 54 zoledronic acid Zometa 54 hMG 54 zinc supplementation 54 PDE inhibitors 54 quetiapine Seroquel 54 PROMETA Treatment Program 54 lowering LDL cholesterol 54 CYP#D# inhibitors 54 phenelzine 54 T1DM 54 Parnate 54 FSAD 54 STAT3 signaling 54 CLBP 54 basal insulin analogue 54 somatoform disorder 54 elevated homocysteine 54 teratogenic 54 stepwise approach 54 proguanil 54 glucose abnormalities 54 cardiovascular morbidity 54 causal pathways 54 genetic loci 54 visit www.BYETTA.com 54 Surgical excision 54 Ampakine compounds 54 prenatal multivitamin 54 chromosomal rearrangement 54 contra indications 54 glycaemia 54 GI motility disorders 54 venous thromboembolic disease 54 KRAS variant 54 cytostatic 54 H2 antagonists 54 neuro psychiatric disorders 54 empiric treatment 54 virologic suppression 54 dopamine antagonists 54 SPIRIVA HandiHaler 54 pre operatively 54 Femara letrozole 54 omeprazole Prilosec 54 allergen immunotherapy 54 radioimmunotherapy RIT 54 interventional therapies 54 RLY# 54 beta interferons 54 HuLuc# 54 androgen depletion therapy 54 ELBW infants 54 Vidaza azacitidine 54 sacral neuromodulation